Fausto J. Rodriguez M.D., Johns Hopkins School of Medicine Report from funding, 2011-2012. This study has been published in two journals. Pilocytic astrocytomas (PA) are low grade neoplasms that represent the most frequent gliomas in children and your adults. Most of these tumors have an excellent outcome after gross total resection. However a subset progress …
Sarah Rush, M.D., University of Denver Two-year funding, 2010-2011 Juvenile pilocytic astrocytomas (JPA) are common tumors of childhood. Despite the high incidence, the biological factors that influence outcomes for these children remain poorly understood. Based on our preliminary data, IMP3 represents a highly specific prognostic marker for JPA allowing for improved prediction of outcome. The aim …
PI: Fausto J. Rodriguez M.D., Johns Hopkins Medical Institute new 2011-2012, one-year Patients with pilocytic astrocytoma (PA) generally have favorable outcomes following surgical intervention, although a subset may cause significant morbidity or mortality, despite lack of atypical histologic features. Unlike diffuse gliomas, increased proliferation, invasive growth pattern, and/or necrosis do not always predict aggressive behavior …
Charles Eberhart, M.D., Ph.D. 2010-2011 funding Diffuse intrinsic pontine gliomas (DIPG) are among the most deadly pediatric brain cancers, with no effective therapies. Unfortunately, few models for these exist, severely limiting our ability to test new treatments for the patients who need them most. The goal of our research proposal is to develop accurate models …
Leigh Marcus, M.D., National Cancer Institute Special Project funded 2010-2011 We would like to thank the CBTF for supporting our phase 1 clinical trial of Satraplatin in children with brain tumors. Although overall survival for children with CNS tumors is rising, new agents that are more effective and less toxic are desperately needed. Chemotherapeutic agents …
Kathy Warren, M.D., NCI Special Project funded 2010-2011 Children with diffuse intrinsic pontine gliomas (DIPG) continue to have a poor outcome despite advances in radiation oncology, new chemotherapeutic agents and extensive research into overcoming drug resistance. One of the major obstacles is the lack of biological studies that may aid us in better understanding the …
PI: Joseph Scafidi, DO, Children’s Research Institute Grant duration, Aug. 2011–Sept. 2013. New, first year summary. Childhood is a critical time because of rapid growth and development of the brain. During this period, the brain’s white matter, composed of myelin, is the last structure to fully mature. There is growing evidence that a disturbance in …
PI: Susan M. Mendrysa, Ph.D., Purdue University First year, August 2011- September 2012, Funding duration 2011-2013 Medulloblastoma (MB) is the most common malignant brain cancer of childhood. Although mutations in the p53 tumor suppressor protein are found in the majority of human cancer, p53 mutations are rare in MB tumors. This suggests that alternative events …
The Childhood Brain Tumor Foundation and Children’s National Medical Center partnered again in the collaboration of the Childhood Cancer Survivorship Conference, Focus on Brain Tumors, on Sunday, May 22, 2011. The comprehensive conference included excellent topics and expert speakers from the region who shared their knowledge. If you are interested in any information that was covered, please …